InMed Pharmaceuticals (INM) Cash from Operations Growth (1y) (2020 - 2026)
InMed Pharmaceuticals (INM) Cash from Operations Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 81.06% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 8.26% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -46.22% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 63.59% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 73.78% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 33.73% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 16.88% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.03 Mn | 790,206.45 | - | -2.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.15% |
| Dec 31, 2025 | 5.03% |
| Sep 30, 2025 | 12.00% |
| Jun 30, 2025 | -72.81% |
| Mar 31, 2025 | 14.21% |
| Dec 31, 2024 | -35.39% |
| Sep 30, 2024 | 15.98% |
| Jun 30, 2024 | -56.42% |
| Mar 31, 2024 | -16.76% |
| Dec 31, 2023 | 31.88% |
| Sep 30, 2023 | 3.61% |
| Jun 30, 2023 | 83.74% |
| Mar 31, 2023 | 69.03% |
| Dec 31, 2022 | 23.22% |
| Sep 30, 2022 | 15.01% |
| Jun 30, 2022 | -101.75% |
| Mar 31, 2022 | -15.99% |
| Dec 31, 2021 | -96.17% |
| Sep 30, 2021 | -93.49% |
| Jun 30, 2021 | -43.43% |